Podcasts about Pharma

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA has rejected Capricor's therapy for Duchenne Muscular Dystrophy (DMD), causing shares to plunge due to insufficient evidence of effectiveness for cardiomyopathy associated with DMD. Lilly and Sarepta also received Complete Response Letters (CRLs) for their therapies. Moderna has won full approval for its COVID-19 vaccine for higher-risk kids, while Pacira has cut staff in San Diego. The FDA has released a cache of CRLs, providing insights into the journeys to market for various drugs. AbbVie has acquired Ichnos Glenmark's lead myeloma antibody, and Ultragenyx's stock plummeted after a late-stage trial disappointment. Kennedy postponed a preventive care panel meeting after a Supreme Court win. Transitioning from one piece of news to the next, let's move on to the webinar exploring digitization strategies for drug development. Stay tuned for more updates in the pharmaceutical industry.

AI is racing ahead, but for industries like life sciences, the stakes are higher and the rules more complex. In this episode, recorded just before the July heatwave hit its peak, I spoke with Chris Moore, President of Europe at Veeva Systems, from his impressively climate-controlled garden office. We covered everything from the trajectory of agentic AI to the practicalities of embedding intelligence in highly regulated pharma workflows, and how Veeva is quietly but confidently positioning itself to deliver where others are still making announcements. Chris brings a unique perspective shaped by a career that spans ICI Pharmaceuticals, PwC, IBM, and EY. That journey taught him how often the industry is forced to rebuild the same tech infrastructure again and again until Veeva came along. He shares how Veeva's decision to build a life sciences-specific cloud platform from the ground up has enabled a deeper, more compliant integration of AI. We explored what makes Veeva AI different, from the CRM bot that handles compliant free text to MLR agents that support content review and approval. Chris explains how Veeva's AI agents inherit the context and controls of their applications, making them far more than chat wrappers or automation tools. They are embedded directly into workflows, helping companies stay compliant while reducing friction and saving time. And perhaps more importantly, he makes a strong case for why the EU AI Act isn't a barrier. It's a validation. From auto-summarising regulatory documents to pulling metadata from health authority correspondence, the real-world examples Chris offers show how Veeva AI will reduce repetitive work while ensuring integrity at every step. He also shares how Veeva is preparing for a future where companies may want to bring their LLMs or even run different ones by geography or task. Their flexible, harness-based approach is designed to support exactly that. Looking ahead to the product's first release in December, Chris outlines how Veeva is working hand-in-hand with customers to ensure readiness and reliability from day one. We also touch on the broader mission: using AI not as a shiny add-on, but as a tool to accelerate drug development, reach patients faster, and relieve the pressure on already overstretched specialist teams. Chris closes with a dose of humanity, offering a book and song that both reflect Veeva's mindset, embracing disruption while staying grounded. This one is for anyone curious about how real, applied AI is unfolding inside one of the world's most important sectors, and what it means for the future of medicine.

Things may be getting serious for Ireland's pharma industry after Tuesday's threat by Donald Trump to impose a 200% tariff on US pharma companies who fail to repatriate their production within a timeline. What would that mean for Ireland? Bobby is joined by economist Cormac Lucey & David Anchell, the founder and managing director of Camida.

Merck Serono S.A. v. Hopewell Pharma Ventures, Inc.

What's really lurking in our waters—and are we being told the truth? In this explosive kickoff to Rush to Reason, Dr. Kelly Victory and Steve House join John Rush to question the latest media alarm over Vibrio infections. Is this just another case of public health fear-mongering, or a subtle push for a climate change agenda? Could the endless warnings actually be causing Americans to tune out real dangers? And what about weather manipulation—are recent floods in Texas just nature, or something more controlled? The conversation is just getting started, and the questions raised may challenge everything you've been told. That same spirit of skepticism carries into the next segment, where the topic shifts to another hot-button issue: the shingles vaccine. Is it really necessary? Dr. Kelly Victory weighs in with a surprising take—explaining why she doesn't recommend it for most people, despite widespread promotion. Could lifestyle changes and immune-boosting supplements like zinc and vitamin D be more effective than a controversial vaccine with serious side effects? The discussion takes a sharp turn into deeper waters as the hosts uncover what may be a pharmaceutical coup against RFK Jr.—a man challenging Big Pharma, the vaccine industry, and the very foundations of modern healthcare. Is he a dangerous disruptor… or exactly what America needs? Don't miss this heated exchange that asks: Who really controls our health system—and why are they so afraid of change? That question becomes even more urgent in the following segment, where the spotlight widens to reveal how Big Pharma, the food industry, and government bureaucracy have all conspired—knowingly or not—to create a broken, one-size-fits-all system. Disruptors like RFK Jr. are shaking that system to the core, but are they being silenced for it? The hosts debate the real impact of figures like RFK and Elon Musk, from vaccine policy to political reform, and expose how corporate influence shapes both medicine and food. Plus, find out why a simple pre-packaged meal program sparked outrage—and why RFK defended it anyway. Are we witnessing the unraveling of institutional control… or just another round of political theater? Either way, it's a conversation you can't afford to miss. Find out more at https://rushtoreason.com.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The FDA has recently released over 200 complete response letters (CRLs) as part of its initiative to enhance transparency regarding the reasons behind the rejection of new drug and biologics applications. This effort reflects the agency's commitment to being more open with the public about its decision-making processes.In other news, AbbVie has made a significant acquisition by purchasing Ichnos Glenmark's lead myeloma antibody for nearly $2 billion, including a substantial upfront payment of $700 million. However, Ultragenyx and Mereo Biopharma faced challenges as their stocks declined following the announcement that the phase II/III study of their osteogenesis imperfecta candidate did not yield strong results during an interim analysis.Furthermore, there is growing concern surrounding the potential dismissal of the U.S. Preventive Services Task Force, following a Supreme Court ruling that affirmed Health Secretary Robert F. Kennedy Jr.'s authority to remove its members at his discretion. This development has raised questions about the future of preventive health initiatives in the country.For drug developers, finding the right balance between speed and quality is essential for achieving success in the industry. To optimize processes and leverage technology throughout the development journey, new digitization strategies are being explored. Embracing these advancements can help streamline operations and enhance overall efficiency in drug development efforts.

Tune in as Glenn Hunzinger, PwC's Health Industries Leader, connects with Nick Donkar, PwC's U.S. Health Services Deals Leader, and Roel Van den Akker, PwC's Pharma and Life Sciences Deals Leader, to discuss the 2025 midyear deals outlook across health services and pharma and life sciences. They explore how macroeconomic trends, regulatory pressures, and evolving investment strategies are shaping M&A activity and where new opportunities may emerge as companies look ahead to the second half of the year.  Discussion highlights: Health services deal volume remains resilient, with renewed investor interest in behavioral health, physician groups, and home-based care modelsPrivate equity firms are focused on outpatient growth platforms and niche services like revenue cycle management to navigate cost and regulatory headwindsPharma and life sciences dealmaking is centered on targeted, asset driven M&A in the $1 to $5 billion range, rather than full scale platform acquisitionsRegulatory uncertainty from FDA resource constraints to evolving policies on pricing and probability of technical and regulatory success (PTRS), is complicating deal modeling and slowing transaction timelinesU.S. biopharma companies are increasingly sourcing early stage innovation from China, introducing new strategic opportunities along with cross border compliance and data challengesSpeakers:Glenn Hunzinger, Health Industries Leader, PwCNick Donkar, US Healthcare Deals LeaderRoel Van den Akker, US Pharma & Life Sciences Deals Leader Linked materials:https://www.pwc.com/us/en/industries/health-industries/library/health-services-deals-outlook.htmlhttps://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.htmlFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Merck recently made a significant move in the pharmaceutical industry by acquiring Verona for $10 billion, gaining access to the commercial COPD drug Ohtuvayre. This acquisition is viewed as a strategic decision to offset potential revenue loss when the patent for Keytruda expires. In other news, the Supreme Court has suspended an injunction preventing RFK Jr.'s HHS cuts. AstraZeneca also finalized a deal with JCR worth up to $825 million for gene therapy AAVs. Additionally, Trump has threatened 200% pharma tariffs, but has provided a one-year grace period for implementation. Drug developers are being advised to digitize their outsourcing path for optimal success in the industry. Furthermore, Novo Nordisk has terminated a deal with Hims & Hers, while Lilly has received an FDA label update for an Alzheimer's drug. Various developments in the longevity biotech space have also been highlighted. Stay tuned for more updates in the pharmaceutical industry.

As media habits evolve and audiences fragment across screens, pharma marketers are reassessing where and how to show up. Traditional channels face increasing pressure, while new environments — particularly CTV, OTT, and premium video formats like cinema — are gaining ground for their ability to deliver both attention and measurable outcomes. This roundtable explores how pharma can realign its strategy to ensure visibility, resonance, and results in today's shifting media ecosystem.Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register!    AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket!    Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

What if your medicines could be delivered faster than your pizza and by your trusted local pharmacist?In this episode of 21 Min Pharma Edge powered by Game of Pharma, we sit down with Kaushal Shah, the visionary behind eVitalRx and PillO, two startups that are redefining how India experiences pharmacy. From disrupting traditional retail chemists to building a digital backbone for pharmacies, Kaushal Shah walks us through his bold vision for the future. In this episode, we cover:The idea behind delivering medicines in under 60 minutesHow PillO partners with local pharmacies to challenge the giantsBalancing speed, safety, and trust in healthcare delivery If you're curious about the intersection of healthcare, tech, and Indian innovation — this one's a must-watch. Don't forget to like, comment, and subscribe for more episodes of Game of Pharma.Available on YouTube, Spotify, Gaana, JioSaavn, Amazon Music, and Apple Podcasts. #PharmaTech #eVitalRx #PillO #HealthcareInnovation #GameOfPharma #PharmacyStartup #QuickCommerce #HealthDelivery #IndianStartups #KaushalShah #21minpharmaedge #pharmapodcast #pharmacy #pharmacist Kaushal Shah's LinkedIn: https://www.linkedin.com/in/kaushalshah06/Host's LinkedIn: https://www.linkedin.com/in/lokesh-sharma-7250a71a9/Follow us on social media-Website: https://gameofpharma.com/Instagram: https://www.instagram.com/gameofpharma/LinkedIn: https://www.linkedin.com/company/game-of-pharma/

Welcome to Top of the Morning by Mint.. I'm Nelson John and here are today's top stories. Trump Hits Brazil With 50% Tariff In a fiery escalation, U.S. President Donald Trump announced a 50% tariff on all Brazilian imports starting August 1. The move follows a diplomatic spat with Brazil's President Lula da Silva, who called Trump an “unwanted emperor.” Trump fired back with a sharply worded letter defending ex-President Jair Bolsonaro, calling his trial “a witch hunt” and accusing Brazil of censorship and unfair trade. “Brazil has treated Bolsonaro disgracefully,” Trump wrote, adding that the tariffs are just the beginning. A Section 301 investigation into Brazil's digital trade practices is also underway. Trump hinted at possible revisions if Brazil reforms, but warned of further hikes otherwise. #USBrazilTensions #TrumpTariffs #Geopolitics #JairBolsonaro #TradeWar Trump Threatens 200% Pharma Tariff, India Alarmed Trump is now eyeing a 200% tariff on pharmaceutical imports, a move that could hit India's $30 billion pharma exports hard. The threat follows a Section 232 probe launched in April into whether pharma imports pose a national security risk. The U.S. accounts for 31% of Indian pharma exports and sources nearly 40% of its generics from India. Indian manufacturers warn this could worsen drug shortages in the U.S. and disrupt patient care. “Adding tariffs will hurt patients and delay our investments in the U.S.,” said Kathleen Jaeger of the Indian Pharmaceutical Alliance. The final decision is expected soon, and Indian pharma companies are already weighing exit strategies. #PharmaTariffs #IndianPharma #GenericDrugs #TrumpTrade #DrugShortage New US Visa Fee Raises Travel Costs Planning a U.S. trip? Brace for a higher bill. Under Trump's “One Big Beautiful Bill Act,” a new $250 Visa Integrity Fee is in effect for most non-immigrant visas including B1/B2 (tourist/business), F and M (student), H-1B (work), and J (exchange). The fee, described as a refundable “good behavior bond”, is meant to enforce compliance with visa terms—no overstaying or unauthorized work. Starting in 2026, the fee will rise annually with inflation. For Indian travelers, it means the cost of a U.S. tourist visa jumps from $185 to $472 (~₹40,500). Refunds are rare and only apply to those who strictly follow the rules. #USVisaFee #ImmigrationPolicy #H1B #TravelCosts #VisaNews Vedanta Under Fire: “Ponzi Scheme” Allegation Viceroy Research, the short-seller that exposed Wirecard, is now targeting Anil Agarwal's Vedanta Resources. In a damning report, Viceroy labeled the Indian conglomerate a “Ponzi scheme,” citing mismanagement and unsustainable debt. Vedanta has denied the charges, calling them “malicious and baseless.” But co-founder Fraser Perring warned more reports are coming. Viceroy, known for its multi-report takedowns, has a track record of triggering steep stock declines—80% of its targets have suffered. Perring also disclosed that he and his team shorted Vedanta bonds in April. With more revelations likely, investor anxiety is growing. #Vedanta #ViceroyResearch #ShortSelling #FraserPerring #MarketWatch India Scrambles After China Cuts Fertiliser Exports Commerce Minister Piyush Goyal has warned of the risks of overdependence on China for fertiliser supplies, following Beijing's export curbs on Di-ammonium phosphate (DAP)—India's second-most used fertiliser. India imported over 2.5 million tonnes of DAP in FY25, much of it from China. The restrictions have spiked global prices and sparked fears of shortages during the kharif sowing season. Goyal called for diversified sourcing, domestic production boosts, and long-term mineral partnerships. He also projected India's agri-exports could grow from ₹4.5 trillion to ₹20 trillion with better processing and branding. But the short-term focus remains: ensuring farmers have what they need to plant. #FertiliserCrisis #ChinaCurbs #PiyushGoyal #AgriExports #DAPShortage Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textDr. Thomas Ehmer, Ph.D.  ( https://www.linkedin.com/in/tehmer/ ) is a seasoned technology strategist with over two decades of experience in IT innovation, business development, and R&D within the pharmaceutical industry, and co-founder of the Quantum Interest Group, at Merck KGaA Darmstadt, Germany ( https://www.emdgroup.com/en ). Dr. Ehmer currently is in the Sector Data Office - AI Governance and Innovation Incubator at Merck KGaA Darmstadt, Germany, where he scouts emerging and disruptive technologies, demonstrating their potential value for R&D applications, with a focus on quantum technologies. Throughout his career at Merck KGaA Darmstadt, Germany, Dr. Ehmer has played a pivotal role in shaping IT strategy, business process optimization, and digital transformation across the entire pharmaceutical value chain, currently focusing on transparent AI and how and where emerging technology can help patients live a better life. His expertise spans technology scouting, business analysis, and IT program leadership, having successfully driven major global projects. Beyond his corporate career, Dr. Ehmer is an active private seed investor and has contributed to quantum computing research and applications in drug discovery, authoring publications on the potential of quantum computing and machine learning in pharmaceutical R&D ( https://onlinelibrary.wiley.com/doi/10.1002/9783527840748.ch26 ). Dr. Ehmer holds a Ph.D. in Physics, Biophysics, and Physiology from Heidelberg University and continues to mentor within the German Physical Society / Deutsche Physikalische Gesellschaft (DPG). His forward-thinking approach, combined with deep technical expertise, has earned him multiple innovation awards, and he remains dedicated to bridging the gap between emerging technologies and real-world industry applications.Important Episode Link - Entangled Health Podcast - https://podcasts.apple.com/us/podcast/entangled-health/id1819364423#ThomasEhmer #MerckKGaADarmstadt #Physics #Biophysics #Physiology #GermanPhysicalSociety #QuantumComputing #QuantumSensing #MolecularImaging #Spectroscopy #DrugScreening #Diagnostics #QuantumSensors #QuantumMagnetometers #QuantumGravimeters #Biomanufacturing #QualityControl #Neuroscience #BrainDrugInterface #ReservoirComputing #QuantumMachineLearning #Bioconvergence  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Cornelia Lechelmayr, Head of Talent Acquisition bei Inizio Engage, beschreibt den Arbeitsmarkt – insbesondere für die Pharma-Branche – als in der Transformation begriffen.

Just a reminder the legendary Chuck Norris is a whopping 84 years old and yet has MORE energy than most of us — he discovered he could create dramatic changes to his health simply focusing on 3 things that sabotage our body as we age. Watch his method by clicking the link in the description box here: http://ChuckDefense.com/FlyJust a reminder the legendary Chuck Norris is a whopping 84 years old and yet has MORE energy than most of us — he discovered he could create dramatic changes to his health simply focusing on 3 things that sabotage our body as we age. Watch his method by clicking the link in the description box here: http://ChuckDefense.com/Fly http://ChuckDefense.com/FlyToday at 11:11 am CST, on the Flyover Conservatives show we are tackling the most important things going on RIGHT NOW from a Conservative Christian perspective! Today at 11:11 am CST, on the Flyover Conservatives show we are tackling the most important things going on RIGHT NOW from a Conservative Christian perspective! TO WATCH ALL FLYOVER CONTENT: www.theflyoverapp.com TO WATCH ALL FLYOVER CONTENT: www.theflyoverapp.com To Schedule A Time To Talk To Dr. Dr. Kirk Elliott Go To To Schedule A Time To Talk To Dr. Dr. Kirk Elliott Go To ▶ https://flyovergold.com▶ https://flyovergold.comOr Call 720-605-3900 Or Call 720-605-3900 ► Receive your FREE 52 Date Night Ideas Playbook to make date night more exciting, go to www.prosperousmarriage.com► Receive your FREE 52 Date Night Ideas Playbook to make date night more exciting, go to www.prosperousmarriage.comwww.prosperousmarriage.comDr. Troy SpurrillDr. Troy SpurrillWEBSITE: www.officialsynapse.com WEBSITE: www.officialsynapse.com Dr. Troy Spurrill is the founder and CEO of Synapse CeSend us a message... we can't reply, but we read them all!Support the show► ReAwaken America- text the word FLYOVER to 918-851-0102 (Message and data rates may apply. Terms/privacy: 40509-info.com) ► Kirk Elliott PHD - http://FlyoverGold.com ► My Pillow - https://MyPillow.com/Flyover ► ALL LINKS: https://sociatap.com/FlyoverConservatives

In this episode, I go over 8 lessons to maximize your first 90 days in Life Sciences. These include understanding the impact of their roles, adopting a professional mindset, passing the first 90-day test, avoiding the 'silent trap,' finding mentors, valuing feedback, mastering systems, and taking responsibility for their careers. Subhi emphasizes that these lessons can significantly accelerate growth and career advancement for newcomers to the industry.Link to course: subhisaadeh.gumroad.com/l/6figurebiomedical00:00 Introduction: Starting Your Career Journey00:54 Lesson 1: Your Role Can Have a Big Impact02:55 Lesson 2: Adopting a Professional Mindset04:06 Lesson 3: The First 90 Days Are Crucial05:09 Lesson 4: Avoiding the Silent Trap06:35 Lesson 5: Finding the Right Mentors07:14 Lesson 6: Embrace Feedback as Fuel07:51 Lesson 7: Mastering the Systems08:47 Lesson 8: Taking Responsibility for Your Career09:19 Conclusion and Additional ResourcesSubhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations and R&D he's worked in Large Medical Device/Pharma organizations to support the development and launch of Hardware Devices, Disposable Devices, and Combination Products for Vaccines, Generics, and Biologics. Subhi serves currently as the International Committee Chair for the Combination Products Coalition(CPC) and as a member of ASTM Committee E55 and also served as a committee member on AAMI's Combination Products Committee.For questions, inquiries or suggestions please reach out at letscombinate.com or on the show's LinkedIn Page.

SBS Finance Editor Ricardo Gonçalves speaks with Francesco De Stradis from Ord Minnett about the day's sharemarket news including Trump's copper and pharma tariff threats, plys Stephanie Youssef discusses ACMA's latest findings on telco complaints with member Samantha Yorke.

President Trump threatens substantial levies on copper and the pharma sector, as the EU scrambles to agree on a tariff deal. U.S. Commerce Secretary Howard Lutnick says that both sides are making progress. Meta bets on EssilorLuxottica - reportedly taking a $3.5 billion minority stake in the Ray-Ban maker as the U.S. tech giant makes a push in the 'smart glasses' space. Elon Musk lashes out at one of the most bullish Tesla analysts on Wall Street, telling Wedbush Securities' Dan Ives to "Shut up," after he called for Musk to cut back on politics.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

APAC stocks traded mixed following the similar performance stateside where tariff updates remained in focus.US President Trump said he will announce something on pharmaceuticals very soon and will be announcing semiconductor tariffs, believes the copper tariff will be 50%.President Trump said the US is probably two days off from sending the EU a letter, which means a deal.European equity futures indicate a slightly higher cash market open with Euro Stoxx 50 future up 0.3% after the cash market closed with gains of 0.6% on Tuesday.DXY is a touch higher with the USD mixed vs. peers (stronger vs. havens, weaker vs. antipodeans).RBNZ maintained the OCR at 3.25%, as expected, hinted at future rate cuts ahead.Looking ahead, highlights include BoE FSR, FOMC Minutes, RBA's Hunter, BoE Governor Bailey, ECB's Lane, Nagel & de Guindos, Supply from UK, Germany & US.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Cliff Taylor, Columnist with The Irish Times; and Simon McKeever, CEO Irish Exporters Association

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Medical societies, including the American Academy of Pediatrics, have filed a lawsuit against RFK Jr. over changes to COVID-19 vaccine policies. They argue that his directive to remove COVID-19 from vaccination guidelines for healthy pregnant women and children puts them at risk of serious illness. Concentra has acquired struggling biotech company Cargo Therapeutics in a $200 million buyout. President Trump's tax law has restored orphan drug exemptions, cut Medicaid funding, and threatened the 340B program, while giving pharmacy benefit managers a pass. The ALS community has petitioned the FDA to reconsider Brainstorm's cell therapy Nurown, citing recent survival data. Drug developers are exploring new digitization strategies to optimize processes and embrace technology in drug development. Overall, the text discusses legal action against RFK Jr. over vaccine policy changes, recent acquisitions in the biotech industry, implications of Trump's tax law on healthcare programs, petitions regarding ALS therapies, digitization strategies in drug development.

It's been less than a month since the annual adland bonanza, but Cannes continues to drive industry headlines.Some campaigns shined through and earned industry plaudits, including a number of efforts touching on relevant – in some cases, controversial – health topics.One of them is No More Hippocrites, which was developed by sexual health telehealth company Wisp and its agency partner Eversana Intouch, a 2025 MM+M Agency 100 honoree. In this week's episode, reporter Heerea Rikhraj delves into No More Hippocrites with Ivan Blotta, head of art and creative excellence at Eversana Intouch – unpacking the work and examining how it earned a Silver Pharma Lion at Cannes.Then, we discuss the health-related provisions included in the recently-passed One Big Beautiful Bill, including a few that might serve as a boon for pharma companies.Music: “Deep Reflection” by DP and Triple Scoop Music. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

After trading in a tight range for most of the session, frontline indices bounced back sharply in the final hour—but can the momentum hold? In today's Market Minutes, we decode the day's biggest market triggers, from sectoral action and fund flows to key business updates from heavyweights like Tata Motors, and JSW Steel. Globally, US President Trump has reignited trade tensions with sweeping new tariff threats—slapping a 50% duty on copper and warning of 200% tariffs on pharma exports. In our Voice of the Day segment, Amit Kumar Gupta, Founder of Fintrekk Capital, unpacks the possible fallout for Indian pharmaceutical exporters.  Tune in for all this and more in today's Market Minutes — your morning podcast bringing you the top stories to kickstart your trading day, from stocks in the news to macro trends and global market cues.

Medical cannabis is booming—but with growth comes scrutiny. As regulations tighten, producers face one critical question: is your lab up to pharmaceutical-grade standards? For more, visit https://hempirelabs.com Hempire Labs S.L. City: Sotogrande Address: C.C., Mar y Sol Local 3.9 Website: https://hempirelabs.com

Gigi Robinson grew up with Ehlers-Danlos syndrome, a disease that turns your joints into overcooked spaghetti. Instead of letting it sideline her, she built a career out of telling the truth about invisible illness. We talk about what it takes to grow up faster than you should, why chronic illness is the worst unpaid internship, and how she turned her story into a business. You'll hear about her days schlepping to physical therapy before sunrise, documenting the sterile absurdity of waiting rooms, and finding purpose in the mess. Gigi's not interested in pity or polished narratives. She wants you to see what resilience really looks like, even when it's ugly. If you think you know what an influencer does, think again. This conversation will challenge your assumptions about work, health, and what it means to be seen.RELATED LINKSGigi Robinson Website: https://www.gigirobinson.comLinkedIn: https://www.linkedin.com/in/gigirobinsonInstagram: https://www.instagram.com/itsgigirobinsonTikTok: @itsgigirobinsonA Kids Book About Chronic Illness: https://akidsco.com/products/a-kids-book-about-chronic-illnessFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Discord Channel: https://discord.gg/pqKsMKp6SA LIVE today at 2 pm PT on Trader Merlin Here's what we're covering in today's episode:

After a month away from home, the Boys In Gold returned to Geodis Park and secured all 3 points late against Philadelphia Union.  As always, thanks for listening! 

In this week's episode of the EMJ GOLD Podcast, Matt Mortimer Ryan, Senior Global Marketing Manager, Vaccines, GSK, shares his perspective on how understanding patients' emotional drivers can unlock more impactful, insight-led disease awareness campaigns.  Matt joins Isabel to discuss what true patient-centric marketing looks like in practice, how to translate behavioural insights into smarter strategies, the advice he'd give his younger self and much more.  A little more on EMJ GOLD's guest…  Matt is a global marketing leader at GSK, driven by a passion for human-centered innovation in the pharmaceutical industry. With more than 20 years of experience at GSK, Pfizer and Danone, he combines his scientific curiosity with strategic creativity to accelerate meaningful outcomes for patients. The views expressed in this interview are Matt Mortimer-Ryan's own and do not necessarily represent those of GSK.  

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Kalvista has received approval for the first on-demand hereditary angioedema pill after facing challenges with the FDA. Meanwhile, Robert F. Kennedy Jr. has made significant cuts and rehires at the Department of Health and Human Services. Upcoming biopharma milestones to watch include developments in obesity and rare genetic diseases, as well as therapies targeting the TIGIT space. Drug developers are exploring digitization strategies to optimize processes and embrace technology in the development journey amidst a busy buyout period in the pharmaceutical industry.Transitioning to the next news, the text discusses four therapies targeting TIGIT that are still holding on in a troubled space where many others have failed. It also highlights the potential of using AI and genetics to reduce adverse drug reactions and restore public trust in the pharmaceutical industry. Additionally, it mentions the FDA's decision to remove risk evaluation and mitigation strategies for certain cell and gene therapies, as well as recent developments in ultrarare therapies, cancer treatments, and regulatory changes. The text provides information on the HHS overhaul by the numbers, including rehiring hundreds of employees but still operating with reduced staff.

The Big Unlock Podcast · Aligning AI Fundamentals with User Experience in Pharma – Podcast with Alicia Abella In this episode, Alicia Abella, AI Product Lead at Novo Nordisk, discusses how she is helping drive responsible AI adoption in the pharmaceutical industry. She shares her early experiences in AI, starting with her PhD research at Columbia University on image processing and natural language processing.  At Novo Nordisk, the current focus is on applying AI to commercialization functions including – marketing, legal, and HR – beyond its traditional use in drug discovery. Alicia highlights key use cases such as generative AI for knowledge search, content generation for marketing campaigns, and traditional AI techniques for deriving insights about healthcare providers. She also emphasizes the importance of applying a product mindset to AI development by evaluating user needs, business value, and compliance from the outset. Alicia notes that adding effective governance can help innovation move in the right direction. She also talks about an internal AI Ambassador Program and emphasizes the importance of designing intuitive AI tools to increase adoption. She concludes by discussing future trends in AI, including contextual intelligence, user-centric design, and the opportunity for AI to enhance, rather than replace human decision-making. Take a listen.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Breakthrough in Cancer TreatmentExciting news in the world of oncology as a new breakthrough in cancer treatment has been announced. Researchers have discovered a novel therapy that targets specific mutations in cancer cells, leading to significantly improved outcomes for patients. This groundbreaking treatment is set to revolutionize the way we approach cancer care and could potentially save countless lives in the future.## FDA Approval for New DrugIn other news, the FDA has granted approval for a new drug that shows promising results in the treatment of a rare genetic disorder. This drug has undergone rigorous testing and has been shown to be both safe and effective in clinical trials. The approval of this medication represents a major milestone in the field of rare disease treatment and offers hope to patients who previously had limited options for managing their condition.## Collaboration between Pharmaceutical CompaniesA collaboration between two leading pharmaceutical companies has been announced, with the goal of developing innovative therapies for a range of diseases. This partnership brings together the unique expertise and resources of both companies, potentially leading to the discovery of new treatments that could benefit patients worldwide. This collaboration highlights the importance of working together to address unmet medical needs and advance the field of medicine.## Advancements in Gene TherapyExciting advancements have been made in the field of gene therapy, with researchers reporting promising results in early clinical trials. Gene therapy has the potential to treat a wide range of genetic disorders by replacing or modifying faulty genes. These latest developments represent a significant step forward in the field of genetic medicine and offer hope to patients who previously had limited treatment options.## ConclusionIn conclusion, these recent developments in the world of Pharma and Biotech are not only groundbreaking but also offer hope for patients facing serious medical conditions. From breakthroughs in cancer treatment to advancements in gene therapy, the future of medicine is looking brighter than ever. Stay tuned for more updates on these exciting developments as we continue to follow the latest news in Pharma and Biotech.

Send us a textIn this episode of the Life Science Success Podcast my guest is Frank Jäger, a Commercial Director at CCL Clinical and Managing Director of CCL Faubel, who brings extensive expertise in pharmaceutical labeling, sales, and innovative IoT applications. With a background in economics and a leadership role in multiple companies within the pharmaceutical packaging sector, Frank has been a prominent figure in the industry, serving on the ISPE Steering Committee and delivering insightful presentations on pharmaceutical packaging challenges.00:00 Introduction to Life Science Success Podcast00:34 Meet Frank Jäger: Career Journey and Insights04:48 Transition from Economics to Life Sciences07:36 Role and Responsibilities at CCL Clinical15:38 Innovations and Future Projects31:43 Leadership and Personal Insights36:28 Conclusion and Podcast Wrap-Up

Wristband that provides relief for upper limb tremor is approved; FDA warns of clinically significant weight loss in younger kids taking ADHD meds; REMS removed for CAR T-cell immunotherapies; treatment approved for lung cancer patients with EGFR exon20 insertion mutations; and CDC committee recommends removing preservative from flu vaccines.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people aged 50-59 who are at risk of severe disease, following recommendations from ACIP members he had previously fired. Biogen CEO Chris Viehbacher tried to strike a deal with Sage as the company searched for a way forward after setbacks, but Sage was not interested. In other news, late-stage stumble for Cosentyx sets Novartis back in autoimmune conditions, and Gilead eyes HIV market domination with a twice-yearly treatment. Additional stories include biotech leaders and investors urging the FDA to maintain access to Mifepristone, Regeneron scoring a nod for a bispecific drug for multiple myeloma, and the increasing demand for bioinformatics roles in the industry.

Share your thoughts with meMy Lifestyle and cook book Living Ayurveda is now available on Amazon : https://mybook.to/LivingAyurvedaWe have just finished the first round of Nourish Balance Thrive 8 week online group and it was fantastic! A new round will soon materialise and the number of spots available is limited. Join the wait list for upcoming rounds of NBT program :Email "wait list" Find out more about the program here :https://www.yogicha.com/nourish-balance-thrive-2/

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. A judge has suspended mass layoffs at the Department of Health and Human Services, ruling that the staff cuts are likely unlawful as the agency does not have the authority to make such changes without Congress. In other news, private equity firms have recently acquired Bluebird Bio, a gene therapy biotech company, raising questions about their motivations. Additionally, RFK Jr. is advocating for changes to the vaccine injury compensation program to include COVID-19 vaccines, while the FDA is considering regulatory action on Argenx's Vyvgart Hytrulo due to safety concerns. The article also discusses Gilead's plans for dominance in the HIV market with a new drug, and other updates in the pharmaceutical industry.Private equity firms are increasingly targeting biotech companies, with Bluebird Bio recently being acquired by two firms. The first half of the year saw a surge in M&A activity in the pharmaceutical industry, with big pharmas like Eli Lilly and Novartis making multiple deals. Deals related to Alzheimer's disease also saw a significant increase following the approval of new treatments. Gilead is expanding its presence in the HIV market with a new drug, while GSK is also vying for market dominance. Other notable deals include AbbVie's acquisition of Capstan and Novartis' partnership for cardiovascular disease targets. Overall, the industry is seeing increased activity and interest from private equity firms and big pharma companies.

In this MM+M Fast Break, MM+M's Heerea Rikhraj sits down with Dr. Julius Wilder to chat about “Steps Ahead”, a new documentary focused on the issue of health equity and health disparities folks in Durham, North Carolina face. The documentary was produced in collaboration with Health Monitor Network. Check it out here.  Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

The Boys In Gold keep showing just how tough they are to beat. The 13 game unbeaten streak continues and NSC will have a chance to go top of the league this weekend against Philadelphia Union.  Thanks for listening! 

Send us a textIn this episode of the Life Science Success Podcast my guest is Sameer Lal, a highly respected pharma veteran and business leader with three decades of experience in advancing the life sciences industry through technological innovation. With his strategic vision and people-first approach, Sameer has been instrumental in helping pharma CXOs navigate digital transformation and is currently serving as the SVP-Enterprise Medical Solutions at Indegene, where he has played a pivotal role in the company's remarkable growth and leadership in generative AI.00:00 Introduction to Life Science Success Podcast00:29 Meet Sameer Lal: Pharma Veteran and Business Leader01:21 Sameer's Journey in Life Sciences04:01 Technological Evolution in Pharma05:53 Generative AI in Pharma: The Third Wave08:23 Indegene's Role and Sameer's Leadership20:54 Challenges and Opportunities with Generative AI24:44 Leadership Insights and Personal Reflections35:12 Conclusion and Final Thoughts

Content managed by ContentSafe.coSupport the show

In this episode of Let's Combinate, Archana shares her insights on the critical factors involved in designing clinical trials, from phase one safety profiling to pivotal phase three trials. She also discusses the importance of patient diversity, the ethical considerations in clinical research, and the future of clinical trials, including decentralized trials and the use of advanced technologies. The conversation highlights the intricate balance between maintaining rigorous scientific standards and adapting to new methodologies to enhance patient recruitment and data integrity. Time Stamps: 00:00 Welcome and Introduction 00:28 Understanding Clinical Trial Design 00:58 Phases of Clinical Trials 02:27 Oncology Trials and Patient Pathways 05:00 Protocol Design and Regulatory Considerations 08:40 Patient Preferences and Vendor Selection 18:53 Types of Clinical Trials 23:01 Understanding BA and BE Studies 24:39 Clinical Coordination of BA/BE Studies 25:15 Infrastructure and Emergency Management in Clinical Trials 26:19 Addressing Mistrust in Clinical Trials 29:54 Ensuring Diversity in Clinical Trials 32:41 The Rise of Decentralized Clinical Trials 39:06 Challenges and Solutions in Decentralized Trials 42:49 Technology and Regulation in Clinical Trials 47:28 Final Thoughts and Contact InformationArchana Sah is a Clinical development thought leader with extensive (30 years) experience and passion for developing medicines for patients having led and contributed to 15 FDA/EMEA drug approvals including Tecentriq® in multiple indications and combinations, Alecensa®, Polivy®, Hemlibra®, Gazyva®, Pixuvri®. She has held various global positions within Biotech, Big pharma, CRO including Genentech/Roche, Bayer Oncology, Johnson & Johnson, ICON, and two Oncology biotech start up companies. She has also worked in healthcare technology as the Senior Vice President of Digital and Decentralized Solutions at Medable Inc. She is now an independent strategy consultant and Board Advisor and provides strategic advisory services to pharma, biotechs, digital healthtech software companies, venture firms in clinical development and operations as well as on leveraging innovative patient centered digital health technologies in a fit for purpose approach to improve diversity, access and efficiencies within the healthcare ecosystem. She has been honored as Top20 women in immuno oncology drug development and featured in PharmaFEATURES on Oncology drug development and Digital Health technology.She has routinely led several industry collaboration consortiums. She is the co-founding chair and member of Society for Clinical Research Sites Oncology Board and chaired the Annual Oncology Summits. She is a current Mentor for the CancerX Moonshot program dedicated to revolutionizing advancements in cancer care, clinical trials, patient support, biotech & pharma and drive integration of digital tools in oncology. She serves on the Leadership Council for Decentralized Trials and Research Alliance(DTRA) and as their Evidence/Publications Librarian. She also serves as an Advisor to American Cancer Society Cancer Action Network (ACS CAN) and is a reviewer for the international Journal of the American Cancer Society "Cancer". Invited advisor and keynote/speaker at several industry conferences.Contact: archana.sah@aspharmaadvisors.comSubhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations, and R&D, he has worked in large Medical Device and Pharma organizations to support the development and launch of hardware devices, disposable devices, and combination products for vaccines, generics, and biologics.Subhi currently serves as the International Committee Chair for the Combination Products Coalition (CPC), is a member of ASTM Committee E55, and has served on AAMI's Combination Products Committee.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Beckley's psychedelic nasal spray, BPL-003, has successfully cleared Phase II trials for treatment-resistant depression, showing robust efficacy data. Analysts predict the asset could reach peak market sales of $1 billion. This paves the way for late-stage development and a proposed merger with atai life sciences. In other news, M&A activity saw a significant increase in June, with big pharmas like Eli Lilly, Sanofi, and Novartis making multiple deals. The FDA's decision to remove risk evaluation and mitigation strategies from approved CAR T cancer therapies has been well-received by the cell and gene therapy community. Additionally, Argenx has made a $1.5 billion acquisition of Unum Therapeutics' macrocyclic peptides, aimed at "undruggable" targets. Moderna, Merck, UroGen, and other companies received regulatory nods for various treatments in June. Evotec is hosting a webinar on preserving quality in the pharma industry amidst financial challenges on July 16. Job opportunities in the industry include positions at Biomarin Pharmaceutical Inc., Regeneron Pharmaceuticals, and AbbVie.

In this special episode of the MM+M Podcast, we sit down with Dr. Osama Hashmi — dermatologist, cofounder and chief product officer at Impiricus — alongside practicing physician Dr. Bilal Ahmed — an interventional/structural cardiologist, cofounder and CSO of Lylah, a personalized microbiome therapeutics company — to explore how artificial intelligence is transforming the way healthcare professionals connect with pharmaceutical resources. We'll dive into how Impiricus and the life science companies it works with are building and leveraging the first and only AI-powered field force enhancement tool designed to streamline real-time communication between HCPs and pharma reps. From clinical decision support to on-demand access to drug information, this conversation unpacks how technology can bridge long-standing gaps in care delivery and engagement.Tune in for a forward-looking discussion on the evolving needs of clinicians, the role of AI in healthcare and how pharma can better support providers in delivering optimal patient outcomes.  Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Pharma commercialization is more of an art than a science.While the focus of an executive is always on the science, the job requires a certain degree of tact. This week, senior pharma editor Lecia Bushak speaks with Justin Holko, SVP of the global oncology/hematology commercial business unit at Regeneron Pharmaceuticals, about the top commercial and marketing trends in pharma.For the second half of the show, the team delves into the paradigm-shifting vaccine advisors meeting. The new look, RFK Jr.-selected ACIP met and recommendations have been made – so what now?Music: “Deep Reflection” Artist - DP and Triple Scoop Music. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Episode Description:If you've ever wondered what happens when a Bronx-born pediatric nurse with stage 4 colon cancer survives, raises a kid, becomes a policy shark, and fights like hell for the ignored, meet Vanessa Ghigliotty. She's not inspirational. She's a bulldozer. We go way back—like pre-Stupid Cancer back—when there was no “young adult cancer movement,” just a handful of pissed-off survivors building something out of nothing. This episode is personal. Vanessa and I built the plane while flying it. She fought to be heard, showed up in chemo dragging her kid to IEP meetings, and never stopped screaming for the rest of us to get what we needed. We talk war stories, progress, side-eyeing advocacy fads, TikTok activism, gatekeeping, policy wins, and why being loud is still necessary. And yeah—she's a damn good mom. Probably a better one than you. You'll laugh. You'll cry. You'll want to scream into a pillow. Come for the nostalgia. Stay for the righteous anger and iced coffee.RELATED LINKSVanessa on LinkedInColorectal Cancer Alliance: Vanessa's StoryZenOnco Interview with VanessaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In my opinion, Tucker Carlson's interview with RFK was a softball, limited hangout. Lot's of red meat for anti-vaxxers but no questions of true import.Here are a few of the questions I would have asked if I were to interview Secretary Kennedy:1. Why haven't you reversed the former HHS secretary's COVID-19 Public Health Emergency?2. Why haven't you used the bully pulpit to bring awareness and aid to the vaccine injured & dead?3. Why haven't you used the bully pulpit to publicly advocate for the PHARMA liability shields to be abolished?4. Why haven't you used your position as HHS secretary to withhold funding from states that enforce severe vaccine mandates for babies and children?5. Why haven't you pulled the mRNA shots OFF the market while you study them for safety?6. Why did you fast track SA-mRNA vaccines?7. Why is your agency still recommending COVID shots for immune compromised babies and pregnant mothers?8. Why hasn't your agency advised health practitioners to post ingredients lists, package inserts and potential adverse reactions for ALL vaccines to achieve true 'informed consent'?9. Why haven't you directed NIH director Jay Battacharya to launch a massive, nationwide study on vaccine related injuries and deaths?Is it any surprise RFK has never appeared on the SJ Show?Today we discuss this and more with special guest Seth Holehouse!Last week Ed Dowd warned of deep recession and recommended GOLD as the PREMIER safe haven, saying ‘gold is money good' … a Tier 1 asset.It is time to get your metals strategy in place! Call the company I trust, Colonial Metals Group today to learn about a gold strategy that works for you and see if you qualify for up to $7,500 in FREE silver! Check out my landing page here: https://colonialmetalsgroup.com/joyWe discuss this and MORE today on the SJ Show!Join the Rumble LIVE chat and follow my Rumble Page HERE so you never miss an episode: https://rumble.com/c/TheShannonJoyShowShannon's Top Headlines July 1, 2025:Ed Dowd Recommends GOLD: https://usawatchdog.com/gold-is-money-good-brace-for-deep-recession-ed-dowd/Trumps BBB Spells Fiscal Disaster: https://brownstone.org/articles/washingtons-fiscal-doomsday/BIS - Stablecoins FAIL As Money: https://www.technocracy.news/battle-line-drawn-bis-says-stablecoins-fail-as-money/Alex Jones Warns Of July 4 ‘Bioterror' Attack: https://x.com/newstart_2024/status/1939387250900619496SJ Show Notes:Please support Shannon's independent network with your donation HERE: https://www.paypal.com/donate/?hosted_button_id=MHSMPXEBSLVTSupport Our Sponsors:The Joy family is obsessed with Native Path Complete Protein!! It is the BEST way to get the protein your body needs EVERY day and it's on sale exclusively for the SJ audience!Go to https://nativepathcompleteprotein.com/joy today to claim your EXCLUSIVE 41% off deal before it's gone.With lockdowns looming, threats of bio-terror and cyber attacks, the chaos is everywhere. You NEED to be prepared and your one stop shop is The Satellite Phone Store. They have EVERYTHING you need when the POWER goes OUT. Use the promo code JOY for 10% off your entire order TODAY! www.SAT123.com/JoyPlease consider Dom Pullano of PCM & Associates! He has been Shannon's advisor for over a decade and would love to help you grow! Call his toll free number today: 1-800-536-1368 Or visit his website at https://www.pcmpullano.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Chris Notter sits down with Kendy Choi, Director of Commercial and Partnerships at Cainiao, to explore her fascinating journey through the air cargo world — from pharmaceuticals and live animals to the evolving landscape of e-commerce. Kendy shares how she helped shape Liège's cargo operations from the ground up, discusses the industry's digital transformation, and dives into how AI, data integration, and collaboration are redefining logistics. Whether you're in aviation, logistics, or just love hearing from forward-thinking leaders, this one's for you.

Sure this sounds like it's coming direct from scripture (it is), as these are some of the exact healing miracles Jesus himself is renowned performed.  What we can tell you is there's more...MUCH more...in this episode.  Further, there's not a single invasive technology required for these miracles you'll see and hear discussed.  In fact, this is water derived straight from the book of Genesis, here to heal God's children...already, 8 clinical studies have been completed to prove 100% of the people have astounding results.  (Even better - big Pharma can't touch it, plus it's even blessed by RFK Jr's MAHA).  This show is nothing short of spectacular. 

In the premiere episode of The Executive Dose, host Stephen Beckman—CEO of YARAL Pharma—sits down with Nicholas Hart, CEO of IBSA USA, for a timely and insightful conversation on the forces shaping the pharmaceutical industry in 2025. From supply chain disruption and regulatory pressure to innovation in both branded and generic sectors, these two leaders explore how today's pharma CEOs are steering through uncertainty and preparing for the next wave of transformation. Key Topics Discussed: Introduction to The Executive Dose and its mission to spotlight leadership perspectives in pharma. Stephen Beckman shares his journey leading YARAL Pharma, the U.S.-based generics subsidiary of global healthcare leader IBSA Group.   Hart, CEO of IBSA USA, joins to discuss market dynamics from the branded side of the business. Why this conversation matters in today's complex and rapidly evolving healthcare environment. What's shaping pharma today—global uncertainty, supply chain instability, and shifting regulatory frameworks. The evolving relationship between branded and generic innovation: where the most impact is happening. How executives are leading through volatility while maintaining patient-centric growth strategies. The importance of resilient leadership, cross-sector collaboration, and long-term portfolio planning. Emphasis on strategic alignment, regulatory agility, and mission-driven innovation. Predictions for the next 3–5 years: What will define success in pharma? How R&D, commercialization, and market access are being reimagined. Advice for rising leaders in the pharmaceutical space: Be bold, stay grounded, and lead with purpose. Episode Takeaways: Innovation isn't just about products—it's about mindset, agility, and leadership. Both branded and generic companies have a role in shaping the future of accessible, high-quality care. Strategic foresight and collaboration will define the next era of pharmaceutical growth.

Send us a textLisa Pratta and her 33 years experience in Big Pharma joins King Hap and his 15 years to discuss FALSE CLAIMS “ONE INSIDER'S IMPOSSIBLE BATTLE AGAINST BIG PHARMA CORRUPTION”. Her new hit book that help rock the pharmaceutical industry.Lisa began working for the government and gathering intel to try and stop the craziness, fraud, and danger that big pharma were trading off for profit!CheckOut her website and book https://www.lisapratta.com/Follow her on Instagram https://www.instagram.com/lisaprattaThis episode was recorded live on the network infront of Happy Hour V.I.P.sIf you want to be part of the live tapingsfollow us on Twitchhttps://m.twitch.tv/thehappyhourscorwww.TheHappyHourSocialClub.comAS ALWAYSThe Happy Hour is brought to you by the official Top Shelf Alcohol of the Happy Hour!CLEARWATER DISTILLERY https://shop.clearwaterdistilling.com/PROMO CODE KINGHAPSAVES 10% and free shipping over $100OLD SCHOOL LABSAmazing Supplements made for Amazing people!TRY OATMEAL CREAM PIE PROTEIN! Save 15% site wide with promo code Kinghaphttps://shop.oldschoollabs.com/?aff=364